Titration

The Worldwide Lateral Flow Assays Industry is Expected to Reach $10.2 billion by 2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, February 22, 2021

The global lateral flow assays market is projected to reach USD 10,230.3 million by 2025 from USD 8,205.3 million in 2020, at a CAGR of 4.5% during the forecast period.

Key Points: 
  • The global lateral flow assays market is projected to reach USD 10,230.3 million by 2025 from USD 8,205.3 million in 2020, at a CAGR of 4.5% during the forecast period.
  • Wide applications of lateral flow assays in food safety and environment testing promote the growth of this segment in the forecast period.
  • In the lateral flow assay kits & reagents by technique segment, sandwich assays holds the highest market share
    On the basis of technique, the lateral flow assay kits & reagents market is segmented into competitive assays, sandwich assays, and multiplex detection assays.
  • North America is expected to account for the largest share of the global lateral flow assays market in 2019.

Global Immunofluorescence Assay Market (2020 to 2026) - Increasing Government Funding for Life Science Research is Driving Growth

Retrieved on: 
Tuesday, February 16, 2021

Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years.

Key Points: 
  • Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years.
  • The kits segment accounted for the highest growth rate in the Immunofluorescence assay market, by product, during the forecast period
    The Immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories.
  • The kits segment accounted for the highest growth rate in the Immunofluorescence assay market in 2020.
  • Factors such as improving healthcare infrastructure, increasing healthcare spending, and favorable government initiatives are driving the growth of the immunofluorescence assay market in Asia-Pacific.

New Found Intercepts 28.4 g/t Au over 13.8m and 25.0 g/t Au over 10.3m at Keats, Provides Exploration Overview

Retrieved on: 
Thursday, February 11, 2021

High-grade assay intervals received to date at Keats have correlated directly with the observation of significant visible gold in drill core.

Key Points: 
  • High-grade assay intervals received to date at Keats have correlated directly with the observation of significant visible gold in drill core.
  • The Company is utilizing the observation of visible gold in drill core as the primary method to guide step-out drilling at Queensway.
  • Assay results received from drilling to date have outlined an approximate 115m strike length of a thick, high-grade zone of gold mineralization at Keats.
  • We are continuing to step out on it to the north, to the south, and to depth.

LexaGene’s MiQLab Successfully Detects Mutant UK and South African COVID-19 Sequences

Retrieved on: 
Wednesday, February 10, 2021

This is a unique feature that is not found in any other system designed for point-of-care use.

Key Points: 
  • This is a unique feature that is not found in any other system designed for point-of-care use.
  • Dr. Jack Regan, LexaGenes CEO and Founder states, Just three weeks ago, we designed assays to detect the UK and SA variants to demonstrate proof-of-principle that these assays could be quickly ported onto the MiQLab.
  • After just two full work days of having these reagents in-house, we verified our MiQLab could detect mutations associated with these variants.
  • The MiQLab system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately one hour.

Sun Summit Commences Drill Program at Buck; Identifies Visible Gold in Discovery Hole BK20-012

Retrieved on: 
Tuesday, February 9, 2021

Sun Summit commences an aggressive follow-up drill program to target high-grade gold mineralization.

Key Points: 
  • Sun Summit commences an aggressive follow-up drill program to target high-grade gold mineralization.
  • Select samples from hole BK20-012 are being analysed for metallic screen fire assay to better characterise the grade of the visible gold-bearing zones.
  • The identification of visible gold throughout our discovery hole is significant and confirms our assay data.
  • Drill crews are now onsite, and the drill is currently investigating the extent of high-grade gold mineralization identified in drill hole BK20-012.

ams selects Extra Horizon to power innovative point-of-care cloud solution for its lab-quality, spectral sensor-enhanced Lateral Flow Test solution to help fight COVID-19 (SARS-CoV-2)

Retrieved on: 
Wednesday, February 3, 2021

The combination of the ams spectral sensor and Extra Horizons connected solution pave the way for a range of digital point-of-care tests, including extremely fast and highly accurate lateral flow (immuno assay) tests.

Key Points: 
  • The combination of the ams spectral sensor and Extra Horizons connected solution pave the way for a range of digital point-of-care tests, including extremely fast and highly accurate lateral flow (immuno assay) tests.
  • In fact, a full production line for SARS-CoV-2 antibody digital rapid tests has already been inaugurated as a result of the technology .
  • Extra Horizon offers best-in-class GDPR-compliant medical-grade cloud solutions through their deeply proven expertise in medical cloud, says Pierre Laboisse, Executive Vice President Global Sales and Marketing, ams.
  • The software component of the point-of-care sensor solution is powered by Extra Horizons robust and fully compliant backend solution.

Bio-Techne Announces Expanded Simple Plex Immunoassay Cartridge Portfolio

Retrieved on: 
Wednesday, February 3, 2021

MINNEAPOLIS, Feb. 3, 2021 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple PlexTM immunoassay cartridge portfolio to include nine new cartridge formats.

Key Points: 
  • MINNEAPOLIS, Feb. 3, 2021 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) today announced that ProteinSimple, a Bio-Techne brand, has expanded its Simple PlexTM immunoassay cartridge portfolio to include nine new cartridge formats.
  • These new cartridge offerings provide Simple Plex users with increased flexibility in the number of samples and biomarker assays run on each cartridge.
  • Simple Plex assay cartridges, run on the EllaTM platform, utilizing state-of-the-art microfluidics to deliver a fully automated immunoassay solution.
  • Factory calibration of each Simple Plex assay cartridge eliminates the need to generate standard curves.

Meridian’s Air-Dryable Master Mixes Replace Lyophilization in the Manufacturing of Molecular Assays

Retrieved on: 
Tuesday, February 2, 2021

Meridians new air-dryable master mixes for DNA/RNA detection replace the need for lyophilization with a fast, simple and inexpensive oven-drying procedure.

Key Points: 
  • Meridians new air-dryable master mixes for DNA/RNA detection replace the need for lyophilization with a fast, simple and inexpensive oven-drying procedure.
  • A unique advantage of Meridians air-dryable master mixes is their ability to effectively preserve the performance and integrity of the enzymes throughout the oven-drying process.
  • In addition, air-dryable master mixes are ideal for molecular assays that require multiplexing or are price sensitive.
  • Lourdes Weltzien, PhD, Executive Vice President Life Science commented, Air-dryable master mixes create a paradigm shift for molecular assay manufacturers.

Global COVID-19 Diagnostic Demand Outlook, Q1 2021 Report Based on the WHO Health Security Index

Retrieved on: 
Friday, January 29, 2021

DUBLIN, Jan. 29, 2021 /PRNewswire/ -- The "COVID-19 Global Diagnostic Demand Outlook by Country, Assay Volume Quarterly Outlook to December 2021, Separately for Molecular and Serology.

Key Points: 
  • DUBLIN, Jan. 29, 2021 /PRNewswire/ -- The "COVID-19 Global Diagnostic Demand Outlook by Country, Assay Volume Quarterly Outlook to December 2021, Separately for Molecular and Serology.
  • This report looks at the assay volume demands by country looking out 5 quarters to the end of 2021.
  • The publisher looks at 3 scenarios for pandemic progression and explore diagnostics demand in each scenario.
  • The forecasts are based on the WHO Health Security Index with specific assumptions about the effectiveness of distancing measures and the impact of health system overload on different countries.

Global COVID-19 Diagnostic Demand Outlook Report, Q1 2021 Edition by Country, Assay Volume - Quarterly Outlook to December 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 28, 2021

The "COVID-19 Global Diagnostic Demand Outlook by Country, Assay Volume Quarterly Outlook to December 2021, Separately for Molecular and Serology.

Key Points: 
  • The "COVID-19 Global Diagnostic Demand Outlook by Country, Assay Volume Quarterly Outlook to December 2021, Separately for Molecular and Serology.
  • This report looks at the assay volume demands by country looking out 5 quarters to the end of 2021.
  • The publisher looks at 3 scenarios for pandemic progression and explore diagnostics demand in each scenario.
  • These create varying timelines of demand.